Table 6.
Uni- and multivariate analyses of risk factors for 28-day mortality
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Death at day 28 (n = 43) | Survival at day 28 (n = 163) | Unadjusted hazard ratio (95 % CI) | p valuea | Adjusted hazard ratio (95 % CI) | p value | |
| Age, years | 69 (56–78) | 62 (46–72) | 1.022 (1.003–1.042) | 0.023 | 1.034 (1.011–1.059) | 0.004 |
| Emergency surgery | 24 (56) | 57 (35) | 2.072 (1.135–3.783) | 0.015 | – | – |
| Surgery below the mesocolon | 28 (65) | 128 (79) | 0.561 (0.299–1.050) | 0.075 | 0.427 (0.215–0.848) | 0.015 |
| SOFA score | 10 (7–11) | 7 (4–9) | 1.261 (1.153–1.380) | <0.0001 | 1.291 (1.168–1.427) | <0.0001 |
| SAPS II score | 52 (45–61) | 44 (32–53) | 1.039 (1.019–1.060) | <0.0001 | – | – |
| Initial use of piperacillin-tazobactam | 22 (51) | 105 (64) | 0.636 (0.350–1.157) | 0.117 | – | – |
| Empiric antifungal therapy | 21 (49) | 49 (30) | 1.980 (1.089–3.601) | 0.029 | – | – |
| Other Enterobacteriaceae b | 5 (12) | 34 (21) | 0.538 (0.212–1.366) | 0.195 | 0.342 (0.1219–0.961) | 0.0419 |
| Presence of Candida spp. | 19 (44) | 52 (32) | 1.569 (0.859–2.865) | 0.150 | 2.641 (1.3471–5.179) | 0.0047 |
| Decreased SOFA score at day 3 | 17 (40) | 109 (67) | 0.372 (0.202–0.686) | 0.0015 | 0.311 (0.1632–0.593) | 0.0004 |
| Antibiotic strategy | 0.189 | |||||
| De-escalation | 19 (44) | 91 (56) | 0.488 (0.227–1.051) | 0.566 (0.2503–1.278) | 0.171 | |
| No change | 10 (23) | 21 (13) | Reference | Reference | Reference | |
| Escalation | 14 (33) | 51 (31) | 0.627 (0.278–1.411) | 0.508 (0.2154–1.198) | 0.122 | |
SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment
a p values are from Fisher exact tests or Wilcoxon tests
bOther Enterobacteriaceae: analysis of all Enterobacteriaceae except Escherichia coli, Klebsiella spp., and Enterobacter spp.